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The candidate tumor-suppressor gene hyaluronidase 2 (HYAL2)
encodes a glycosylphosphatidylinositol-anchored cell-surface pro-
tein that serves as an entry receptor for jaagsiekte sheep retrovi-
rus, a virus that causes contagious lung cancer in sheep that is
morphologically similar to human bronchioloalveolar carcinoma.
The viral envelope (Env) protein alone can transform cultured cells,
and we hypothesized that Env could bind and sequester the HYAL2
receptor and thus liberate a potential oncogenic factor bound and
negatively controlled by HYAL2. Here we show that the HYAL2
receptor protein is associated with the RON receptor tyrosine
kinase (also called MST1R or Stk in the mouse), rendering it
functionally silent. In human cells expressing a jaagsiekte sheep
retrovirus Env transgene, the Env protein physically associates
with HYAL2. RON liberated from the association with HYAL2
becomes functionally active and consequently activates the Akt
and mitogen-activated protein kinase pathways leading to onco-
genic transformation of immortalized human bronchial epithelial
cells. We find activated RON in a subset of human bronchioloal-
veolar carcinoma tumors, suggesting RON involvement in this type
of human lung cancer.
The hyaluronidase 2 (HYAL2, also called LUCA2) generesides in a critical 120-kb region of chromosome 3p21.3 that
contains tumor suppressor genes involved in the origin or
development of lung and other human malignancies (1). The
gene encodes a 473-aa protein that is expressed in all human
tissues analyzed including lung (1). HYAL2 is a member of a
large family of hyaluronoglucosaminidases (EC 3.2.1.35) but
exhibits very low hyaluronidase activity (refs. 2 and 3 and
V. Vigdorovich and A.D.M., unpublished results). Recently we
showed that HYAL2 is a glycosylphosphatidylinositol-anchored
cell-surface protein and serves as a receptor for jaagsiekte sheep
retrovirus (JSRV) cell entry (3, 4). In sheep JSRV causes a
contagious form of lung cancer that arises from epithelial cells
in the lower airway including type II alveolar and bronchiolar
epithelial cells (5). In a recent study it was shown that antiserum
directed against the JSRV capsid protein crossreacted with 30%
of human pulmonary adenocarcinoma samples but not with
normal lung tissue or adenocarcinomas from other tissues (6).
Collectively these findings support the possibility (7) of a viral
etiology for some human lung cancers, particularly the bronchi-
oloalveolar adenocarcinoma (BAC) type, which is morphologi-
cally very similar to the sheep tumors (5, 8).
Although there was no known oncogene in JSRV, the JSRV
envelope (Env) protein was shown by us (3) and others (9) to
transform rodent fibroblast cell lines. The cytoplasmic tail of
Env, in particular a YXXM protein motif that is a putative
docking site for phosphatidylinositol 3-kinase (PI3-kinase) after
tyrosine phosphorylation, is important for fibroblast transfor-
mation, which seems to be mediated through the PI3-kinaseyAkt
pathway (10, 11). Transformation has not been explored yet in
epithelial cells, the target for JSRV disease, and the mechanism
of transformation might be different compared with that in
fibroblasts. We hypothesized an alternative model in which the
Env protein could sequester the HYAL2 receptor in the cyto-
plasm and thus liberate a potential oncogenic factor bound and
negatively controlled by HYAL2 in normal bronchial epithelial
cells. Here we provide evidence for this model and document a
pathway for epithelial cell transformation that involves HYAL2
interactions with the RON receptor tyrosine kinase.
Materials and Methods
Expression Vectors. Plasmid pHA-Jenv was made by inserting
sequences encoding a preprotrypsin signal peptide, a hemagglu-
tinin tag, and JSRV Env amino acids 73–615 into the pCR3.1
expression vector (Invitrogen). Plasmid pJenv-V5 was made by
inserting the entire coding sequence of JSRV Env into the
pcDNA3.1DyV5-His-TOPO vector (Invitrogen). Both of these
plasmids also confer resistance to G418. The pFlag-HYAL2
construct has been described (3). The human wild-type RON
cDNA was cloned into the pCI-neo vector (Promega). Kinase-
dead RON (RONkd) was obtained by mutagenesis as described
(12), and this cDNA and an enhanced GFP (EGFP) cDNA were
cloned into the pMSCV-puro vector (CLONTECH) to make
pMSCV-puro-RONkd and pMSCV-puro-EGFP, respectively.
Cell Lines. BEAS-2B cells were a gift from Curtis C. Harris
(National Cancer Institute) and were grown in LHC-8 medium
(13). Human embryonic kidney 293 cells (HEK293), lung ade-
nocarcinoma (NCI-H2122), lung alveolar carcinoma (SW-1573),
and BAC cell lines (NCI-H358, NCI-H650, NCI-H1650, and
NCI-H1781) were from American Type Culture Collection. The
RE7 cell line [Madin–Darby canine kidney (MDCK) cells stably
expressing human RON] has been described (14). HEK293, lung
cancer, and RE7 cell lines were cultured in DMEM containing
10% FBS.
Antibodies. The antibodies used were anti-RON (C-20) rabbit
polyclonal sc-322 and anti-Akt goat polyclonal sc-1618 from
Santa Cruz Biotechnology; anti-HYAL2 C-terminal rabbit poly-
clonal from Research Genetics (Huntsville, AL); anti-mitogen-
activated protein kinase (MAPK) monoclonal M12321 from
Transduction Laboratories (Lexington, KY); anti-phospho-
MAPK monoclonal 9106 and anti-phospho-Akt rabbit poly-
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clonal 9271 from New England Biolabs; anti-Flag M2 monoclo-
nal 05-447 and anti-PY monoclonal (clone 4G10) 05-321 from
Upstate Biotechnology (Lake Placid, NY); anti-V5 mouse
monoclonal R960-25 from Invitrogen; anti-hemagglutinin rabbit
polyclonal antibody 3808-1 from CLONTECH; and rhodamine
conjugated goat anti-rabbit secondary antibody 31670 from
Pierce. Nonspecific affinity-purified rabbit antibodies were used
in preliminary experiments to determine the specificity of all our
rabbit affinity-purified antibodies.
BEAS-2B Cell Transfection. Lipofectamine 2000 (Invitrogen) was
used for transfection according to manufacturer protocol. Cells
(80% confluent) grown in six-well plates were first overlaid with
2 ml per well of Opti-MEM (Invitrogen) for 20 min and then
incubated for 6 h with the DNA–Lipofectamine 2000 complexes
(500 ml per well). These were prepared by mixing 5 mg of plasmid
DNA, 250 ml of Opti-MEM, and 250 ml of LHC-8 medium and
incubated for 20 min at room temperature before transfection.
After transfection the mix was removed and replaced by 2 ml of
LHC-8. The next day cells were collected from each well and
seeded into 10-cm dishes. One day after seeding the cells were
treated with selective antibiotics (1 mgyml G418 or 1 mgyml
puromycin). Under these conditions nontransfected cells died
within 5–7 days, whereas stably transfected cells grew as foci in
2–3 weeks, finally replacing the original BEAS-2B cells.
Analysis of Signaling Pathways in Transiently Transfected HEK293 and
RE7 Cells by Immunoprecipitation and Western Blotting. HEK293
and RE7 cells were transiently transfected with pFlag-HYAL2
andyor pJenv-V5 plasmids by using Lipofectamine 2000 accord-
ing to manufacturer protocol. Forty-eight hours after transfec-
tion the cells were starved overnight in medium without serum
and lysed in lysis buffer (50 mM Hepes, pH 7.4y150 mM
NaCly10% glyceroly1 mM EDTAy1 mM sodium orthovana-
datey10 mM sodium pyrophosphatey100 mM NaFy1% Triton
X-100y10 mg/ml leupeptiny10 units/ml aprotininy1 mM PMSF).
Insoluble material was removed by centrifugation. Molecules of
interest were immunoprecipitated from the cleared lysates by
appropriate antibodies added to lysates together with protein
G-agarose. After overnight incubation at 4°C, immunoprecipi-
tates were washed three times with HNTG buffer (50 mM
Hepesy150 mM NaCly0.1% Triton X-100y10% glycerol), 23
SDSyPAGE sample buffer was added, and the samples were
boiled for 5 min. Proteins were separated by SDSyPAGE and
transferred to nitrocellulose membranes. Protein bands on the
membrane were visualized with appropriate antibodies by stan-
dard Western blotting procedures. For detection of MAPK and
Akt activation, total-cell lysates were used for SDSyPAGE and
Western blotting. For some experiments, to visualize the Env–
HYAL2 complex formed intracellularly, cells were treated with
N-acetyl-Leu-Leu-norleucinal (ALLN; Sigma), an inhibitor of
proteasomal enzymes.
Results and Discussion
The BEAS-2B cell line was established by infection of normal
human bronchial epithelial cells with an adenovirus-12 simian
virus 40 (SV40) hybrid virus (13). The cells retain epithelial
features, grow indefinitely in culture, express the SV40 large T,
show minimal karyotypic changes, retain the ability to undergo
squamous differentiation, and are not able to form tumors in
Fig. 1. Effects of JSRV Env expression in BEAS-2B cells. BEAS-2B cells were transfected with pHA-Jenv (Env) or the empty pCR3.1 expression vector (Control) and
grown in the presence of G418 (see Materials and Methods). (A) Cells were photographed 6 weeks after transfection. The arrow points to a transformed focus.
(B) RT-PCR was used to detect the presence of Env mRNA in transfected cells (Left), and immunofluorescence staining was used to detect the expression and
subcellular localization of JSRV Env protein (Center and Right). For staining, cells grown on coverslips were fixed, permeabilized, and processed as described (18).
Cells were stained with anti-hemagglutinin antibody then secondary goat anti-rabbit antibody conjugated with rhodamine and were counterstained with
49,6-diamidino-2-phenylindole. (C) RON receptor was immunoprecipitated (IP) from cell lysates by anti-RON antibodies. RON tyrosine phosphorylation was
detected by Western blotting (WB) with anti-PY antibodies (Top). RON was detected by using anti-RON antibodies (Middle). The two bands represent mature
RON (lower band) and its intracellular precursor (upper band). HYAL2 was detected with anti-HYAL2 antibodies (Bottom). IP control, immunoprecipitations of
BEAS-2B control cell lysates with nonspecific rabbit IgG antibodies in place of RON antibodies followed by Western blotting as indicated. (D) Activation of Akt
and MAPK in cell lysates was determined by Western blotting with anti-phospho-Akt and anti-phospho-MAPK antibodies. The amount of Akt and MAPK (the
two bands represent p42 and p44 ERK1yERK2) was determined by reprobing of the membrane with anti-Akt and anti-MAPK antibodies. The positions of
molecular mass markers are indicated at right.
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nude mice (13, 15). Interestingly, it was shown recently that
expression of the SV40 early region was an essential first event
in the multistep transformation of primary normal human lung
epithelial cells (16, 17). We transfected the BEAS-2B cells with
a JSRV Env expression plasmid. Six weeks later the stably
transfected cells had grown into numerous piled-up foci (Fig.
1A). These were expanded and analyzed further. First, we
showed by RT-PCR and immunofluorescence microscopy that
the Env transgene was expressed in these cells (Fig. 1B). Second,
using immunoprecipitation and Western blotting with specific
antibodies we showed that in BEAS-2B control cells the HYAL2
protein was associated with an inactiveydormant form of the
receptor tyrosine kinase RON (MST1R, also known as Stk in the
mouse) (Fig. 1C). In Env-transformed cells RON was not
associated with HYAL2 anymore and became activated proba-
bly through autophosphorylation (Fig. 1C) indicating that the
glycosylphosphatidylinositol-anchored HYAL2 protein nega-
tively regulates RON receptor signaling. The implied ability of
HYAL2 to bind hyaluronan present in the extracellular matrix
may strengthen its association with RON further and thereby
block RON signaling pathways. Fig. 1D shows that activation of
RON in Env-transformed cells is associated with constitutive
activation of Akt (19) and MAPKs (20). The natural ligand for
RON is macrophage-stimulating protein (MSP); however, in this
case RON activation was ligand-independent, because we could
not detect MSP in culture medium exposed to BEAS cells or
BEAS cells transfected with the JSRV Env expression plasmid
(,0.1 nM), whereas MSP could be clearly detected in medium
to which purified MSP was added at 0.1 and 1 nM concentrations
(see Supporting Text and Fig. 7, which are published as support-
ing information on the PNAS web site, www.pnas.org). Conse-
quently, activation of Akt and MAPK pathways would drive
proliferation and promote cell survival, both necessary for
malignant transformation and maintenance of the transformed
phenotype (21). Both Akt and MAPK have been shown to be
activated directly by kinase-active RON involving their upstream
targets in each of the respective pathways (22, 23).
To characterize further the properties of the Env-transformed
BEAS-2 cells, we first examined their growth potential in culture
as compared with control cells transfected with an empty vector.
The transformed cells formed 15 times more foci (Fig. 2 A and
B) and grew much faster and to a higher density than nontrans-
formed cells (Fig. 2C). We next examined whether Env-induced
transformation mediated by activated RON could be reversed by
ectopic expression of RONkd (12) or HYAL2. Overexpression
of RONkd blocked production of transformed foci by JSRV Env
(Fig. 2 A and B) and blocked Env-induced increases in cell-
growth rate and maximum density (Fig. 2C). Ectopically over-
expressed RONkd abrogated the activation of Akt and MAPK
pathways (Fig. 2D) and reversed the growth properties of the
Fig. 2. Reversion of Env-induced transformation of BEAS-2B cells by stable expression of RONkd. BEAS-2B cells were transfected with equal amounts of the
following plasmids: Control, pCR3.1 and pMSCV-puro-EGFP; Env, pHA-Jenv and pMSCV-puro-EGFP; EnvyRONkd, pHA-Jenv and pMSCV-puro-RONkd. Transfected
cells were cultured in the presence of G418 and puromycin to select for the expression of both plasmids. (A) Cells photographed 6 weeks after transfection. The
arrow indicates a focus of Env-transformed cells. (B) Control, Env, and EnvyRONkd cells were fixed and stained with Giemsa dye, and foci were counted by using
a microscope. Bars represent the number (mean 6 SE) of foci counted in 25 fields (316 magnification) in three independent experiments. (C) Cells were seeded
at 2 3 104 cells per well in duplicate wells of 24-well plates. Cell numbers were measured at the indicated time points by using a 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) cell-growth determination kit (Sigma). The number of cells was determined from an MTT calibration curve generated
for each cell line. Each experimental point represents the mean 6 SE of three independent experiments. (D) RON, Akt, MAPK, and their tyrosine-phosphorylated
forms were detected as described for Fig. 1. The intensity of the RON bands is noticeably less in the Env-transformed cells as compared with Fig. 1C because of
rapid turnover and recycling of activated RON during continuous culture of transformed cells. The dense RON band in EnvyRONkd cells represents overexpressed
RONkd. The positions of molecular mass markers are indicated at right. IP, immunoprecipitated; WB, Western blot.
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transformed cells (Fig. 2 A–C), indicating that RON activation
is essential for both transformation and maintenance of the
transformed phenotype. HYAL2 overexpression also blocked
transformation by Env (’0.4 foci versus ’20 foci per cm2 after
4 days of growth). Our results show that HYAL2 negatively
regulates the function of the RON receptor tyrosine kinase in
bronchial epithelial cells.
BEAS cells are difficult to transfect, so for further studies we
used highly transfectable MDCK (which do not express RON or
MSP) and HEK293 cell lines to allow facile detection of protein
interactions and modifications such as tyrosine phosphorylation.
We first used a variant of MDCK cells (RE7) stably expressing
high levels of human RON (14) to study the effects of Env
andyor HYAL2 expression. JSRV Env induced ligand-
independent RON and MAPK activation, both of which were
reduced by coexpression of HYAL2 (Fig. 3 A and B). In this
system we did not observe tyrosine phosphorylation of the Env
protein (Fig. 3C). Also, in these cells overexpression of Env
disrupted RON–HYAL2 association by competitively binding
HYAL2 (Fig. 3D). HYAL2 was expressed at similar levels in the
presence or absence of Env, and Env expression was not affected
by HYAL2 coexpression in these cells (Fig. 3E).
We next analyzed these interactions in HEK293 cells, which
express very low levels of endogenous RON and HYAL2
proteins. In this system we showed that (i) the Env protein was
processed properly but not tyrosine-phosphorylated (Fig. 4A),
(ii) RON tyrosine phosphorylation was directly dependent on
the level of Env expression (Fig. 4C), and (iii) Env competed with
RON for binding to HYAL2 (Fig. 4D). Note that in these
experiments (Fig. 4 C and D) and those described above with
MDCK cells (Fig. 3), the cells were treated with the proteasomal
inhibitor ALLN to inhibit protein degradation. Without such
treatment, HYAL2 is degraded to undetectable levels in the
presence of Env (Fig. 4B). Interactions in transiently transfected
MDCK and HEK293 cells involving Env, HYAL2, and RON and
the impact on RON activation are consistent with the proposed
mechanism of Env-induced transformation of immortalized
bronchial epithelial cells.
We tested the prediction that RON activation could be
involved in the development of human lung cancer. Indeed, we
detected RON activation, as measured by RON tyrosine phos-
phorylation, in three of four human BAC cell lines (Fig. 5, lanes
2 and 4–6) and in one lung adenocarcinoma (Fig. 5, lane 1),
indicating a possible role of RON in BAC pathogenesis. It should
be emphasized that mutational analysis of RON in these cell lines
and other lung tumor samples did not reveal any mutations (data
not shown) (see Supporting Text). Recently, overexpression of
RON in distal lung epithelial cells in transgenic mice has been
show to induce peripheral adenocarcinomas (24), further sup-
porting a role for RON in lung cancer. Future studies would be
necessary to elucidate the mechanisms of HYAL2 inactivation in
BAC and other common lung adenocarcinomas. These studies
need to focus on understanding the regulation of cellular RON
by HYAL2 as well as the molecular mechanism(s) by which
HYAL2 impacts RON silencing and its possible interaction with
hyaluronan in the extracellular matrix.
The mechanism of JSRV Env transformation of epithelial cells
presented here (summarized in Fig. 6) is quite different from
Fig. 3. Effects of Env and HYAL2 expression on RON activation in RE7 epithelial cells. RE7 cells were transiently transfected with an empty vector (Control),
pJenv-V5 (Env), pFlag-HYAL2 (HYAL2), or both pJenv-V5 and pFlag-HYAL2 (Env1HYAL2). Two days later cells were incubated overnight in DMEM without serum
in the presence of the proteasomal inhibitor ALLN (see Materials and Methods). After incubation the cells were lysed and analyzed by immunoprecipitation (IP)
and Western blotting (WB). (A and B) RON, MAPK, and their tyrosine-phosphorylated forms were detected as described for Fig. 1. (C) Env was immunoprecipitated
from transiently transfected RE7 cells with anti-V5 antibody. Expression was detected by Western blotting with anti-V5 antibody (Upper). The upper arrow on
the left shows the position of the full-length Env protein. The lower arrow on the left points on the transmembrane domain (TM) of the Env protein generated
by cleavage of the Env protein with endoplasmic proteases. Tyrosine phosphorylation of the Env protein was probed with anti-PY antibody (Lower). The arrows
on the right show the positions of Ig heavy chains (IgH). (D) HYAL2 was detected in Env precipitates with anti-HYAL2 antibodies and in RON immunoprecipitates
with anti-Flag antibody. Arrows on the right show the positions of HYAL2. (E) Expression of Env was detected with anti-V5 antibody and HYAL2 was detected
with anti-Flag antibody in RE7 total-cell lysates. The positions of molecular mass markers are indicated at the right in all panels.
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that proposed for 208F rat and NIH 3T3 mouse fibroblasts,
where the cytoplasmic tail of the Env protein is thought to
interact with PI3-kinase to stimulate the PI3-kinaseyAkt path-
way leading to transformation (10, 11). Indeed, mouse Hyal2
seems to play no role in transformation of NIH 3T3 mouse cells,
because the Hyal2 protein from mouse NIH 3T3 cells functions
very poorly as a receptor for JSRV and binds JSRV Env very
weakly if at all, and overexpression of the mouse Hyal2 does not
suppress transformation by JSRV Env, as expected if Hyal2
functions as a tumor suppressor (27). Furthermore, NIH 3T3
cells do not express Stk, the mouse ortholog of RON, thus the
model for transformation we propose for epithelial cells cannot
be active in these mouse fibroblasts. It has been reported that a
Fig. 4. Effects of Env expression in HEK293 cells. (A) HEK293 cells were transiently transfected with an empty vector (Control) or pJenv-V5 (Env) plasmid. Env
protein was detected as described for Fig. 3. The upper arrow on the left indicates the position of the full-length Env protein, and the lower arrow indicates the
position of the transmembrane domain of the Env protein. Tyrosine phosphorylation of the Env protein was probed with anti-PY antibody (Right). The positions
of Ig heavy chain (IgH) proteins are shown. IP, immunoprecipitated; WB, Western blot. (B) HEK293 cells were transiently transfected with an empty vector
(control), HYAL2, or HYAL2 and Env expression vectors. Forty-eight hours after transfection the cells were treated with or without ALLN proteasome inhibitor
overnight, and total-cell lysates were prepared and analyzed as indicated. (C) HEK293 cells were transiently transfected with 5 mg of pCIneo-RON wild type, 5
mg of pFlag-HYAL2, and increasing amounts of pJenv-V5 plasmid. Two days later cells were incubated overnight in DMEM without serum in the presence of the
proteasomal inhibitor ALLN (see Materials and Methods). After incubation the cells were lysed and analyzed. RON and tyrosine-phosphorylated RON was
detected as described for Fig. 1. Env protein was detected in total-cell lysates with anti-V5 antibodies. Only the Env transmembrane bands are shown, but the
full-length Env showed parallel changes in abundance. (D) HEK293 cells were transiently transfected as described for B. The presence of HYAL2 in RON
immunoprecipitates was detected by anti-Flag antibody (Top). The presence of HYAL2 in Env immunoprecipitates was detected by anti-HYAL2 antibodies
(Middle). HYAL2 was detected in total-cell lysates with anti-Flag antibody (Bottom). The positions of molecular mass markers are indicated at the right in all
panels.
Fig. 5. RON tyrosine phosphorylation in human BAC cell lines. RON and
tyrosine-phosphorylated RON were detected as described for Fig. 1. Two
milligrams of total protein was analyzed in each lane. The positions of mo-
lecular mass markers are indicated at the right. IP, immunoprecipitated; WB,
Western blot.
Fig. 6. Model of Env-mediated transformation of human bronchial epithe-
lial cells. (A) BEAS-2B cells express RON receptor tyrosine kinase (Fig. 1). RON
is expressed on the cell surface as an inactive dimer (25). Association of HYAL2
with RON prevents RON activation. (B) JSRV interacts with HYAL2 via the Env
protein. This interaction leads to viral entry and subsequent sequestration of
HYAL2 by expressed Env and intracellular degradation of HYAL2-Env complex
by a proteasomal-dependent mechanism (Figs. 3D and 4 C and D). Removal of
HYAL2 from the RON complex may cause conformational changes in the RON
kinase domain triggering RON catalytic activity. RON constitutive activation
induces activation of oncogenic pathways involving MAPK and Akt causing
cell transformation. Human and animal BAC tumors are commonly composed
of three types of cells, namely Clara, mucin-producing, and alveolar type II
cells, none of which express RON in normal lung (26). However a common
progenitor cell for these cell types, which probably gives rise to BAC, may
reside in the bronchiolar compartment and may express RON (26). The het-
erogeneity of the differentiation phenotype within BAC lesions has been well
established.
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tyrosine residue at position 590 (Y590) of the intracellular
portion of the JSRV Env is essential for transformation of NIH
3T3 cells by Env, implying phosphorylation of Y590 and subse-
quent activation of Akt by PI3-kinase bound to Y590 (5, 10). In
contrast, we have not found phosphorylation of Y590 in MDCK
(Fig. 4C) or HEK293 (Fig. 4A) cells, again suggesting that the
mechanism of Env transformation is different in fibroblasts and
epithelial cells.
In contrast to most acutely transforming retroviruses that express
oncogenes derived from cellular genes, JSRV, its close relative
enzootic nasal tumor virus (ENTV), avian hemangioma virus
(AHV) (28), and spleen focus-forming virus (SFFV) are members
of a very small group of acutely transforming retroviruses that
express oncogenic Env proteins. Similar to JSRV, the cell-entry
receptor for ENTV is HYAL2, and it is likely that the mechanism
of transformation by ENTV is similar to that of JSRV (4, 11). The
AHV Env can induce transformation andyor apoptosis, but the
mechanism is unknown. SFFV is replication-defective and encodes
a truncated Env protein that does not mediate virus entry. It is
interesting that a naturally occurring truncated form of Stk, the
mouse ortholog of RON, is required for SFFV oncogenesis in mice
(29). This short form of Stk lacks the ligand-binding domain present
in Stk but retains the transmembrane and cytoplasmic tyrosine
kinase domains of Stk. Transformation is mediated through a
complex of the erythropoietin receptor, the SFFV Env, and this
short form of Stk (30, 31).
Our investigation of the molecular interactions leading to
transformation of immortalized human bronchial epithelial cells
by the Env protein of JSRV revealed a tumor-suppressor func-
tion for HYAL2 (summarized in Fig. 6). An important challenge
for future investigations will be to determine whether JSRV or
a similar human virus might be involved in the natural history of
BAC and whether a subset of these tumors might be associated
with other perhaps epigenetic mechanisms of HYAL2 inactiva-
tion. We speculate that treatment of BAC patients with tyrosine
kinase-type inhibitors might be beneficial in view of possible
RON involvement in BAC carcinogenesis as suggested by this
work and the recently published observations that even brief
oncogene inactivation can produce sustained tumor regres-
sion (32).
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